Cargando…
Use of rituximab and the risk of adverse clinical outcomes in COVID-19 patients with systemic rheumatic disease
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Berlin Heidelberg
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7548404/ https://www.ncbi.nlm.nih.gov/pubmed/33044704 http://dx.doi.org/10.1007/s00296-020-04715-0 |
| _version_ | 1783592607525371904 |
|---|---|
| author | Kow, Chia Siang Hasan, Syed Shahzad |
| author_facet | Kow, Chia Siang Hasan, Syed Shahzad |
| author_sort | Kow, Chia Siang |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7548404 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Springer Berlin Heidelberg |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-75484042020-10-14 Use of rituximab and the risk of adverse clinical outcomes in COVID-19 patients with systemic rheumatic disease Kow, Chia Siang Hasan, Syed Shahzad Rheumatol Int Correspondence Springer Berlin Heidelberg 2020-10-12 2020 /pmc/articles/PMC7548404/ /pubmed/33044704 http://dx.doi.org/10.1007/s00296-020-04715-0 Text en © Springer-Verlag GmbH Germany, part of Springer Nature 2020 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
| spellingShingle | Correspondence Kow, Chia Siang Hasan, Syed Shahzad Use of rituximab and the risk of adverse clinical outcomes in COVID-19 patients with systemic rheumatic disease |
| title | Use of rituximab and the risk of adverse clinical outcomes in COVID-19 patients with systemic rheumatic disease |
| title_full | Use of rituximab and the risk of adverse clinical outcomes in COVID-19 patients with systemic rheumatic disease |
| title_fullStr | Use of rituximab and the risk of adverse clinical outcomes in COVID-19 patients with systemic rheumatic disease |
| title_full_unstemmed | Use of rituximab and the risk of adverse clinical outcomes in COVID-19 patients with systemic rheumatic disease |
| title_short | Use of rituximab and the risk of adverse clinical outcomes in COVID-19 patients with systemic rheumatic disease |
| title_sort | use of rituximab and the risk of adverse clinical outcomes in covid-19 patients with systemic rheumatic disease |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7548404/ https://www.ncbi.nlm.nih.gov/pubmed/33044704 http://dx.doi.org/10.1007/s00296-020-04715-0 |
| work_keys_str_mv | AT kowchiasiang useofrituximabandtheriskofadverseclinicaloutcomesincovid19patientswithsystemicrheumaticdisease AT hasansyedshahzad useofrituximabandtheriskofadverseclinicaloutcomesincovid19patientswithsystemicrheumaticdisease |